Clinical Trials Logo

Depression Anxiety Disorder clinical trials

View clinical trials related to Depression Anxiety Disorder.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05530668 Completed - Clinical trials for Depression Anxiety Disorder

Tolerance and Potential Synergistic Effect of the Combination of Intranasal Esketamine and Non-selective MAOI

ESKETAM
Start date: April 11, 2022
Phase:
Study type: Observational

There are already recently published data on the tolerability and efficacy of the combination of ketamine and/or esketamine with MAOIs. However, these reports are few and far between, and to our knowledge, there are no data involving intranasal esketamine. Given the numerous interactions between MAOIs and other antidepressants, and the impossibility of combination, this pharmacological class is neglected. This is despite the fact that MAOIs are the only truly tri-aminergic drugs, that they have unparalleled efficacy in certain forms of resistant apathetic depression, and that new, more dietary permissive forms have appeared on the market. The arrival of antidepressants that can be combined with MAOIs, such as ketamine and esketamine, changes the situation and could offer a new treatment opportunity to many patients in a therapeutic impasse. For these opportunities to become a reality, sharing the clinical experience gained by specialized centers is essential.

NCT ID: NCT04841031 Completed - PTSD Clinical Trials

Psychosocial and Economic Impacts of Narrative Exposure Therapy for Violence Survivors in Eastern DRC

Start date: June 29, 2017
Phase: N/A
Study type: Interventional

The objective of the study is to evaluate the impact of Narrative Exposure Therapy (NET) delivered by local counselors, on the mental health and socio-economic empowerment of survivors of Sexual and Gender Based Violence (SGBV) who suffer Post-Traumatic Stress Disorder (PTSD), in North and South Kivu in Eastern DRC. The counselors will be trained and supervised by clinical experts from the NGO Vivo International. The therapy is expected to reduce the symptoms of PTSD, depression, and anxiety in SGBV survivors. The project is expected to directly impact and improve the beneficiaries' mental health outcomes of interest, and to indirectly impact and enhance their economic empowerment in the medium term and social functioning both in the short and medium term. This proposed impact evaluation will answer the following research questions: 1) What is the impact of NET on survivors' psychosocial wellbeing, economic empowerment and social functioning and participation? 2) Does the impact of NET differ depending on individual and household characteristics as well as context-specific factors?